Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandra Calmy

Showing results (311-320 of 415) with videos related to

Pageof 42
Sort By:
HIV Medicine|October 10, 2023
Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapyLorin Begré, Anders Boyd, Luisa Salazar-Vizcaya, et al.
Plos One|February 11, 2026
Association of a polygenic risk score with low trauma fractures in people with HIV - The swiss HIV cohort studyClaudio Strickler, Christian W Thorball, Isabella C Schoepf, et al.
Swiss Medical Weekly|May 16, 2024
Costs and acceptability of simplified monitoring in HIV-suppressed patients switching to dual therapy: the SIMPL'HIV open-label, factorial randomised controlled trialAnnalisa Marinosci, Delphine Sculier, Gilles Wandeler, et al.
Plos Medicine|November 10, 2020
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trialDelphine Sculier, Gilles Wandeler, Sabine Yerly, et al.
AIDS (London, England)|June 18, 2009
Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring, Olivia Keiser, Hannock Tweya, et al.
The Journal of Infectious Diseases|June 20, 2014
Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wideRoger D Kouyos, Andri Rauch, Dominique L Braun, et al.
BMC Infectious Diseases|March 20, 2024
Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR'HIV): a multicenter, international, non-randomized clinical trial study protocolMaxime Hentzien, Fabrice Bonnet, Enos Bernasconi, et al.
Viruses|April 23, 2022
An Approach to Quantifying the Interaction between Behavioral and Transmission ClustersLuisa Salazar-Vizcaya, Katharina Kusejko, Huldrych F Günthard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 6, 2021
Predicting, Diagnosing, and Treating Acute and Early HIV Infection in a Public Sector Facility in EswatiniBernhard Kerschberger, Aung Aung, Qhubekani Mpala, et al.
Antimicrobial Agents and Chemotherapy|April 4, 2012
Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosisLukas Fenner, Matthias Egger, Thomas Bodmer, et al.
Pageof 42

Showing results (311-320 of 415) with videos related to

Sort By:
Pageof 42
HIV Medicine|October 10, 2023
Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapyLorin Begré, Anders Boyd, Luisa Salazar-Vizcaya, et al.
Plos One|February 11, 2026
Association of a polygenic risk score with low trauma fractures in people with HIV - The swiss HIV cohort studyClaudio Strickler, Christian W Thorball, Isabella C Schoepf, et al.
Swiss Medical Weekly|May 16, 2024
Costs and acceptability of simplified monitoring in HIV-suppressed patients switching to dual therapy: the SIMPL'HIV open-label, factorial randomised controlled trialAnnalisa Marinosci, Delphine Sculier, Gilles Wandeler, et al.
Plos Medicine|November 10, 2020
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trialDelphine Sculier, Gilles Wandeler, Sabine Yerly, et al.
AIDS (London, England)|June 18, 2009
Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring, Olivia Keiser, Hannock Tweya, et al.
The Journal of Infectious Diseases|June 20, 2014
Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wideRoger D Kouyos, Andri Rauch, Dominique L Braun, et al.
BMC Infectious Diseases|March 20, 2024
Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR'HIV): a multicenter, international, non-randomized clinical trial study protocolMaxime Hentzien, Fabrice Bonnet, Enos Bernasconi, et al.
Viruses|April 23, 2022
An Approach to Quantifying the Interaction between Behavioral and Transmission ClustersLuisa Salazar-Vizcaya, Katharina Kusejko, Huldrych F Günthard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 6, 2021
Predicting, Diagnosing, and Treating Acute and Early HIV Infection in a Public Sector Facility in EswatiniBernhard Kerschberger, Aung Aung, Qhubekani Mpala, et al.
Antimicrobial Agents and Chemotherapy|April 4, 2012
Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosisLukas Fenner, Matthias Egger, Thomas Bodmer, et al.
Pageof 42